BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Pharm Country

  Nabriva Therapeutics Added to NASDAQ Biotechnology Index

  This will become effective prior to the open of U.S. markets on Monday, December 18, 2017.

  December 14, 2017

   · 

  4 min read
• Genetown

  Dicerna Announces Pricing of Follow-On Public Offering of 5,714,286 Shares of Common Stock

  Dicerna announced today the pricing of its underwritten registered public offering of 5,714,286 shares of its common stock at a price to the public of $7.00 per share.

  December 14, 2017

   · 

  5 min read
• Business

  Catalyst Biosciences Announces Appointment of Edward Williams to Its Board of Directors

  Mr. Williams was most recently senior vice president of biopharmaceuticals at Novo Nordisk.

  December 14, 2017

   · 

  3 min read
• Drug Development

  Pain Therapeutics Announces New Publication on Alzheimer’s Disease

  The new publication in Neuroimmunology and Neuroinflammation describes an altered form of a protein called filamin A (FLNA) that is critical to the formation of neuropathologies associated with Alzheimer’s disease.

  December 14, 2017

   · 

  3 min read
• Policy

  Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease

  Migalastat previously received both Orphan Drug Designation and Fast Track designation from the U.S. FDA.

  December 14, 2017

   · 

  9 min read
• Business

  Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

  As of September 30, 2017, cash and cash equivalents were $33.9 million, as compared to cash, cash equivalents and short-term investments of $48.8 million as of December 31, 2016.

  December 14, 2017

   · 

  9 min read
• Business

  Medicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the U.S.

  The licensing agreement is for a term of seven years with extensions to the term available.

  December 14, 2017

   · 

  4 min read
• Business

  Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar’s Personalized, Premium Product for Total Gut Health and Wellness in Horses

  According to the terms of the Agreement, Jaguar will pay SEED an ongoing percentage of revenue generated from any clients or partners introduced to Jaguar by SEED, and the agreed-upon revenue percentage increases after the first one-million dollars of revenue.

  December 14, 2017

   · 

  6 min read
• Business

  Axsome Therapeutics Collaborates With World-Leading Nicotine Addiction Research Center for Phase II Trial of AXS-05 in Smoking Cessation

  This collaboration builds upon preclinical research conducted at Duke demonstrating positive effects of the dextromethorphan component of AXS-05.

  December 14, 2017

   · 

  8 min read
• Genetown

  Jounce Therapeutics Added to NASDAQ Biotechnology Index

  The addition will take effect prior to the open of the U.S. markets on Monday, December 18, 2017.

  December 14, 2017

   · 

  1 min read